Ian W. Flinn, MD, PhD

Articles

Dr. Flinn on the Design of a Phase 2 Trial of Zanubrutinib in CLL/SLL

August 31st 2020

Ian W. Flinn, MD, PhD, discusses the design of a phase 2 trial evaluating zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Flinn on Opportunities for Second-Line Tafasitamab in DLBCL

July 14th 2020

Ian W. Flinn, MD, PhD, discusses the opportunity for second-line tafasitamab (MOR208, formerly Xmab®5574) as a palliative treatment of patients with diffuse large B-cell lymphoma.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 9th 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 9th 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL

May 2nd 2018

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.

Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin With AVD in Hodgkin Lymphoma

March 20th 2018

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

Dr. Flinn on 5-Year Follow-up of BRIGHT Study in MCL and iNHL

June 9th 2017

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses 5-year follow-up of the BRIGHT study, which explored the combination of bendamustine and rituximab (BR) versus R-CHOP/R-CVP as a first-line treatment for patients with mantle cell lymphoma (MCL) or indolent non-Hodgkin lymphoma (iNHL).

Dr. Ian Flinn on the Changing Treatment Paradigm for CLL and Low-Grade Lymphoma

February 6th 2015

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses how the approvals of idelalisib and ibrutinib will change treatment paradigms for chronic lymphocytic leukemia (CLL) and low-grade lymphoma.

Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL

December 9th 2014

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Flinn Discusses the DYNAMO Trial

October 14th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Dr. Flinn Discusses IPI-145 as Potential Treatment for Hematologic Malignancies

August 26th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.

Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

December 9th 2013

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).